NATURAL SITE PREFERENCE IN CANCER BIOLOGY
NATURAL SITE PREFERENCE IN CANCER BIOLOGY
批准号:
2087719
负责人:
FRED Raymond MILLER
金额:
$32.62万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1980
资助国家:
美国
项目状态:
已结题
起止时间:
1980-06-01 至 1997-04-30
关键词:
athymic mouse breast neoplasms carcinoma cell line cell transformation chromosome aberrations clone cells cytogenetics disease /disorder model female gene mutation growth factor homeostasis hormone related neoplasm /cancer hyperplasia karyotype mammary epithelium neoplasm /cancer genetics neoplasm /cancer invasiveness neoplastic cell neoplastic process oncogenes preneoplastic state southern blotting xenotransplantation
中文摘要
点击翻译按钮获取中文摘要
英文摘要
In the human breast, a spectrum of microscopic changes has been termed
proliferative breast disease (PBD). Although hyperplastic lesions are
observed in human breast, their role in disease progression is not
understood. The progression of histopathological features of PBD has
been correlated with increased risk for the development of invasive
carcinoma. The most serve form of these lesions are precursors of cancer
or simply markers of breasts likely to give rise to independent
neoplastic lesions. The focal and microscopic lesions of PBD provide
scant tissues for genetic or other biological analyses. A human cell
line (MCF10A) originated from spontaneous immortalization of breast
epithelial cells obtained from a patient with fibrocystic disease.
MCF10A cells do not survive in vivo in Nude or Nude/Beige mice. However,
T25 c-Ha-ras oncogene-transfected MCF10A cells (MCF10AneoT) form small
nodules in Nude/Beige mice. However, T24 c-Ha-ras oncogene-transfected
MCF10A cells (MCF10AneoT) form small nodules in Nude/Beige mice which
persist for at least one year, eventually progress to atypical
hyperplasia, and sporadically progress to carcinomas. MCF10AneoT appear
to be stem cells capable of indefinite proliferation and with a wide
range of differentiation from normal to atypical. By reestablishing
cells in tissue culture from lesions representing different stages in
in which persist for at least one year, eventually progress to atypical
hyperplasia, and sporadically progress to carcinomas. MCF10AneoT appear
to be stem cells capable of indefinite proliferation and different stages
in progression of MCF10AneoT through atypical hyperplasia to carcinomas,
we have been able to provide still snapshots of a dynamic process. These
cell lines continue to progress when reimplanted in vivo in Nude/Beige
mice but are sufficiently stable in vitro to provide the tools essential
for he genetic analysis of progression. Thus, we are able to interrupt
progression by placing cells in vitro and reinitiated progresses in vivo
precipitate overt progression observed in xenografts. This unique model
has great potential for analyzing genetic and epigenetic (i.eg., host-
mediated) events central to progression from normal to atypical
hyperplasia to carcinoma in the human breast. Our hypothesis is that
sequential genetic alterations precipitate changes in human breast
epithelial responses to normal homeostatic regulatory signals. We
hypothesize that the progression of the MCF10AneoT series to malignant
carcinomas is accompanied by changes in homeostatic responses similar to
those which we have described in the mouse, i.e., that tumorigenic
variants of MCF10AneoT will be stimulated by normal epithelium and be
stromal-responsive but not stromal-dependent. Although Ha-ras is not
frequently mutated in human breast cancer, we hypothesize that, in this
model, the ras mutation mimics the effect of other, more common genetic
perturbations and that subsequent alterations driving progression will
be the same in this human breast model as in the natural disease.
Therefore, analysis of genetic changes and homestatic responses with a
series of increasingly aggressive lines will be vitally relevant for the
understanding of early breast cancer progression. A multidisciplinary
attack combining cell biology, molecular biology, and cytogenetics will
be mounted to delineate genetic changes and changes in response to
homeostatic growth regulatory factors which occur at each sequential step
of progression to atypical hyperplasia, to carcinoma in situ, and to
invasive carcinoma in the MCF10AenoT.TG xenograft model.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Proteomics of Progression in MCF10 Xenograft Model
-
批准号:6470342
-
项目类别:
-
资助金额:$24.78万
-
财政年份:2002
-
负责人:FRED Raymond MILLER
-
依托单位:
Proteomics of Progression in MCF10 Xenograft Model
-
批准号:6849197
-
项目类别:
-
资助金额:$23.05万
-
财政年份:2002
-
负责人:FRED Raymond MILLER
-
依托单位:
Proteomics of Progression in MCF10 Xenograft Model
-
批准号:6698074
-
项目类别:
-
资助金额:$23.35万
-
财政年份:2002
-
负责人:FRED Raymond MILLER
-
依托单位:
MCF10DCIS.com as a preclinical chemopreventive screen
-
批准号:6439397
-
项目类别:
-
资助金额:$7.45万
-
财政年份:2002
-
负责人:FRED Raymond MILLER
-
依托单位:
MCF10DCIS.com as a preclinical chemopreventive screen
-
批准号:6620013
-
项目类别:
-
资助金额:$7.45万
-
财政年份:2002
-
负责人:FRED Raymond MILLER
-
依托单位:
Proteomics of Progression in MCF10 Xenograft Model
-
批准号:6623819
-
项目类别:
-
资助金额:$23.87万
-
财政年份:2002
-
负责人:FRED Raymond MILLER
-
依托单位:
LYMPHOKINE-TISSUE INTERACTIONS IN PRENEOPLASIA
-
批准号:2101948
-
项目类别:
-
资助金额:$6.11万
-
财政年份:1993
-
负责人:FRED Raymond MILLER
-
依托单位:
LYMPHOKINE-TISSUE INTERACTIONS IN PRENEOPLASIA
-
批准号:2101949
-
项目类别:
-
资助金额:$14.62万
-
财政年份:1993
-
负责人:FRED Raymond MILLER
-
依托单位:
LYMPHOKINE-TISSUE INTERACTIONS IN PRENEOPLASIA
-
批准号:2101950
-
项目类别:
-
资助金额:$21.65万
-
财政年份:1993
-
负责人:FRED Raymond MILLER
-
依托单位:
LYMPHOKINE-TISSUE INTERACTIONS IN PRENEOPLASIA
-
批准号:3204700
-
项目类别:
-
资助金额:$19.77万
-
财政年份:1993
-
负责人:FRED Raymond MILLER
-
依托单位:
LYMPHOKINE-TISSUE INTERACTIONS IN PRENEOPLASIA
-
批准号:2101951
-
项目类别:
-
资助金额:$22.45万
-
财政年份:1993
-
负责人:FRED Raymond MILLER
-
依托单位:
MODEL TO SEQUENTIALLY ANALYZE THE METASTATIC CASCADE
-
批准号:3423600
-
项目类别:
-
资助金额:$9.22万
-
财政年份:1991
-
负责人:FRED Raymond MILLER
-
依托单位:
MODEL TO SEQUENTIALLY ANALYZE THE METASTATIC CASCADE
-
批准号:3423601
-
项目类别:
-
资助金额:$8.75万
-
财政年份:1991
-
负责人:FRED Raymond MILLER
-
依托单位:
UPGRADING ANIMAL CAGING PREPARATION FACILITIES
-
批准号:3059143
-
项目类别:
-
资助金额:$2.72万
-
财政年份:1990
-
负责人:FRED Raymond MILLER
-
依托单位:
NATURAL SITE PREFERENCE IN MAMMARY CANCER BIOLOGY
-
批准号:3168104
-
项目类别:
-
资助金额:$20.39万
-
财政年份:1980
-
负责人:FRED Raymond MILLER
-
依托单位:
NATURAL SITE PREFERENCE IN MAMMARY CANCER BIOLOGY
-
批准号:3168100
-
项目类别:
-
资助金额:$13.28万
-
财政年份:1980
-
负责人:FRED Raymond MILLER
-
依托单位:
NATURAL SITE PREFERENCE IN MAMMARY CANCER BIOLOGY
-
批准号:3168103
-
项目类别:
-
资助金额:$19.61万
-
财政年份:1980
-
负责人:FRED Raymond MILLER
-
依托单位:
NATURAL SITE PREFERENCE IN MAMMARY CANCER BIOLOGY
-
批准号:3168096
-
项目类别:
-
资助金额:$12.98万
-
财政年份:1980
-
负责人:FRED Raymond MILLER
-
依托单位:
NATURAL SITE PREFERENCE IN CANCER BIOLOGY
-
批准号:2087717
-
项目类别:
-
资助金额:$13.49万
-
财政年份:1980
-
负责人:FRED Raymond MILLER
-
依托单位:
NATURAL SITE PREFERENCE IN CANCER BIOLOGY
-
批准号:2087718
-
项目类别:
-
资助金额:$18.63万
-
财政年份:1980
-
负责人:FRED Raymond MILLER
-
依托单位:
海外基金